Biomedical Engineering Reference
In-Depth Information
CHAPTER 5
Targeting Dipeptidyl Peptidase-4
(DPP-4) and Fibroblast
Activation Protein (FAP) for
Diabetes and Cancer Therapy
F. M. KEANE,
a
S. CHOWDHURY,
a
T.-W. YAO,
a
N. A. NADVI,
a,b
M. G. GALL,
a
Y. CHEN,
a
B. OSBORNE,
a
A. J. V. RIBEIRO,
a
W. B. CHURCH,
b
G. W. M
C
CAUGHAN,
a
M. D. GORRELL*
a
AND D. M. T. YU
a,c
a
Liver Immunobiology, Centenary Institute and Sydney Medical School,
University of Sydney, New South Wales, Australia;
b
Pharmaceutical
Chemistry, Faculty of Pharmacy, University of Sydney, New South Wales,
Australia;
c
School of Engineering and Science—SES Life Sciences, Jacobs
University Bremen, Campus Ring 6, D-28759 Bremen, Germany
5.1 Introduction
In recent years, the dipeptidyl peptidase-4 (DPP-4/CD26) enzyme family,
family S9B (http://merops.sanger.ac.uk), has created intense pharmaceutical
interest. DPP-4 inhibitors have proven successful as a therapy for the growing
type 2 diabetes epidemic and have potential to treat other diseases. Recent
advances have resulted in a large number of DPP-4 inhibitors being in various
phases of clinical development, with five gliptin class inhibitors, alogliptin,
linagliptin, sitagliptin, saxagliptin, and vildagliptin, already in clinical use.
